Base
Notice2026-059062026-03-26

Notice Pursuant to the National Cooperative Research and Production Act of 1993-Biopharmaceutical Manufacturing Preparedness Consortium

Justice Department, Antitrust Division

Document Excerpt

Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Justice Antitrust Division Notice is hereby given that, on October 8, 2025, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. (“the Act”), Biopharmaceutical Manufacturing Preparedness Consortium (“BIOMAP-CONSORTIUM”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, AGC Biologics, Bothell, WA; Anavatos Bio, Inc., Seattle, WA; Cidara Therapeutics INC, San Diego, CA; Crossmhv, L.l.C, Tampa, FL; Defense Operations & Execution Solutions INC, W Melbourne, FL; Health Supply US LLC, Mooresville, NC; Nanopass Technologies Ltd., Nes Ziona, STATE OF ISRAEL; Ommio Health, INC, Woodbridge, CT; UI Pharmaceuticals, Iowa City, IA; Axelyf, Inc., Chestnut Hill, MA; BetteRx Compounding Inc., Smithfield, RI; Crossject SA, Dijon, FRENCH REPUBLIC; Lavik Consulting LLC, Oakland, MO; Nanotag Biotechnologies Gmbh, Goettingen, FEDERAL REPUBLIC OF GERMANY; Quality Assured Artificial Intelligence LLC, Green Cove Springs, FL; Award Advisors, Washington, DC; Beckman Research Institute of the City of Hope, Duarte, CA; Gemini Therapeutics, San Fransisco, CA; Lumacyte, INC, Charlottesville, VA; Modus Operandi, ( printed page 14

Read full document on FederalRegister.gov →

Full Document

Citation: 91 FR 14715